Oculis Holding AG

OCS·NasdaqGM·Healthcare
Compare
7.28−0.35 (−4.59%)today
At close: Nov 4, 4:00 PM EST · May be delayed up to 15 min · USD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close7.63
Open7.60
Day range6.827.89
52-week range6.8234.48
Off day high−7.73%
Off 52-week high−78.88%
Volume550.22K
Avg. volume (3M)261.92K
Market cap448.36M
EPS (TTM)-1.69
Forward P/E-3.81
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)0.29
Shares outstanding61.59M
Short interest3.34% of float
Earnings dateNov 3, 2026
Analyst target37.41
Profit margin0.00%

Against its peers

Compare in full ›
OCS 1477.HK OCGN OVID OCUL YDES
Market cap 448.36M 4.05B 296.55M 535.12M 1.57B 492.28M
P/E (TTM) — — — — — —
Forward P/E -3.8 17.3 -3.5 -7.5 -4.8 —
Price/book 1.8 1.0 -16.8 2.4 3.0 110.3
Dividend yield — — — — — —
1-year change −60.53% −40.60% −47.16% +80.45% −36.91% −39.33%
Today −4.59% +0.30% +17.35% +14.17% +4.69% +7.84%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Related companies

Compare ›

The businesses closest to Oculis's by what they do, from their descriptions, with the same industry weighted in.

Company Mkt cap Price Today
Ocumension Therapeutics1477.HK · Biotechnology 4.05B 5.070 +0.30%
Ocugen, Inc.OCGN · Biotechnology 296.55M 0.8745 +17.35%
Ovid Therapeutics Inc.OVID · Biotechnology 535.12M 2.7400 +14.17%
Ocular Therapeutix, Inc.OCUL · Biotechnology 1.57B 7.14 +4.69%
YD Bio LtdYDES · Biotechnology 492.28M 6.95 +7.84%
Opus Genetics, Inc.IRD · Biotechnology 355.25M 4.2700 +8.65%
OKYO Pharma LimitedOKYO · Biotechnology 75.05M 1.4300 −1.38%
MeiraGTx Holdings plcMGTX · Biotechnology 904.72M 9.42 −1.05%

Other companies in Biotechnology, closest in size first.

Company Mkt cap Price Today
Crescent Biopharma, Inc.CBIO · Waltham, MA 513.37M 13.82 +5.82%
Capricor Therapeutics, Inc.CAPR · San Diego, CA 518.60M 8.92 +8.25%
CytomX Therapeutics, Inc.CTMX · South San Francisco, CA 512.06M 2.3500 +7.80%
MiMedx Group, Inc.MDXG · Marietta, GA 466.96M 3.2000 −1.54%
FluoGuide A/SFLUO.ST · Copenhagen, Denmark 493.75M 30.20 +0.33%
Gyre Therapeutics, Inc.GYRE · San Diego, CA 470.79M 4.4400 0.00%
Monopar Therapeutics Inc.MNPR · Wilmette, IL 488.71M 72.81 +4.18%
Ovid Therapeutics Inc.OVID · New York, NY 535.12M 2.7400 +14.17%

Also based in Zug, Switzerland, then elsewhere in Switzerland.

Company Mkt cap Price Today
Transocean Ltd.RIG · Zug, Switzerland 6.09B 5.45 −7.63%
CRISPR Therapeutics AGCRSP · Zug, Switzerland 5.02B 51.78 +3.57%
Galderma Group AGGALD.SW · Zug, Switzerland 45.55B 195.35 +0.41%
Holcim AG0QKY.IL · Zug, Switzerland 44.93B 74.94 +3.94%
Amrize LtdAMRZ · Zug, Switzerland 23.51B 44.15 +5.19%
Swiss Prime Site AGSPSN.SW · Zug, Switzerland 10.68B 133.10 −0.37%
PSP Swiss Property AGPSPN.SW · Zug, Switzerland 7.15B 155.90 +0.26%
Pharvaris N.V.PHVS · Zug, Switzerland 2.41B 34.33 −1.29%

The stocks whose daily moves over the past year went most closely with Oculis's: the correlation of their daily returns, where 1 would be moving as one.

Company Mkt cap Price Today
NewAmsterdam Pharma Company N.V.NAMS · Correlation 0.32 2.45B 20.93 +5.18%
CytomX Therapeutics, Inc.CTMX · Correlation 0.31 512.06M 2.3500 +7.80%

What visitors to Oculis's page also look at.

Company Mkt cap Price Today
AlvotechALVO 1.67B 4.6700 +2.86%
Mineralys Therapeutics, Inc.MLYS 1.50B 17.00 +6.32%
Entrada Therapeutics, Inc.TRDA 197.02M 5.06 +7.20%
NewAmsterdam Pharma Company N.VNAMS 2.45B 20.93 +5.18%
enGene Therapeutics Inc.ENGN 115.27M 1.7200 +6.17%

From the 4SEARCH.business instruments index: what each company does (its business description), its industry, size, headquarters and the markets it serves; and from a year of daily prices, which move together. Prices may be delayed up to 20 min.

Latest news

All OCS news ›
Seeking Alpha·Negative

Oculis Holding GAAP EPS of -0.30 CHF

Oculis reports Q3 GAAP EPS of CHF -0.30 and CHF 210.3M in cash. - Oculis Holding press release (OCS): Q3 GAAP EPS of -0.30 CHF - As of September 30, 2026, Oculis held cash, cash equivalents and short-term investments of CHF 210.3 million…

OCS
Markets Daily·Positive

Oculis (NASDAQ:OCS) Announces Quarterly Earnings Results

Posted by Danessa Lincoln on Nov 3rd, 2026 Read Our Latest Stock Analysis on OCS Oculis is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company’s research is centered on therapies…

OCSOVVOCGN
Acceldata·

Complete Uninstallation of ODP

To stop all services at once, perform the following: If all the services are not stopped successfully, you need to manually kill all the processes on all nodes by using the following command to list and then kill them. Ambari provides a…

OCSMSFT
markets.businessinsider.com··2 outletsPositive

Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease

High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials Precision Medicine Approach in a Large Market: Licaminlimab is…

More from 1 other outlet

From the 4Search news index, newest first.

In the news

29mentions in 30 days
17with it in the headline
Positivesentiment

Mentioned with

Oculis Holding AG26Board of Directors19Remuneration Committee17Ocugen, Inc.10Chart Oci Holdings Company Ltd4LinkedIn4Nasdaq Helsinki Ltd4Wall Street Zen4

People in the coverage

Oculis25Lionel Carnot21Anthony Rosenberg20Lionel20Geraldine O'keeffe16Gregory Perry16

Themes

Healthcare10SEC Filings9Biotechnology8Equities78-K5Corporate Governance5Earnings5Ocugen5

Most coverage from

  1. themarketsdaily.com6
  2. markets.businessinsider.com5
  3. stocktitan.net4
  4. globenewswire.com3
  5. manilatimes.net3

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 29 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance